Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-600P is a pseudogene derived from the U6 small nuclear RNA (snRNA) gene family. True U6 snRNA plays a central part in spliceosome function and pre-mRNA splicing, but RNU6-600P represents a non-functional genomic copy that arises by retrotransposition or duplication events and does not encode a functional snRNA or protein[1][3]. Pseudogenes can occasionally exert regulatory effects on gene expression by acting as competing endogenous RNAs or by generating regulatory molecules (such as siRNAs or lncRNAs)[2], but RNU6-600P itself does not have documented functional or disease associations. It is present in the human genome as a marker of evolutionary molecular events, not as a pharmacological target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 600, pseudogene (RNU6-600P).